肝病

订阅

MedSci主页 / 所有栏目 / 肝病

Gut：中国研究发现暴露于替诺福韦母婴阻断治疗的胎儿长期安全性良好

2021-05-13 网络 网络

替诺福韦酯
关注

胎儿暴露于预防乙型肝炎母婴传播的富马酸替诺福韦酯(TDF)后，其身体、神经发育长期情况仍不明确。来自我国多中心的研究人员探究了替诺福韦治疗在妊娠晚期的安全性。

胎儿暴露于预防乙型肝炎母婴传播的富马酸替诺福韦酯(TDF)后，其身体、神经发育长期情况仍不明确。来自我国多中心的研究人员探究了替诺福韦治疗在妊娠晚期的安全性。

该研究团队先前开展的随机对照试验（IN-US-174-0174）样本被纳入此次长期随访(LTFU)研究。患慢性乙型肝炎的母亲被随机分配，在妊娠晚期接受或不接受替诺福韦治疗。使用Bayley-Ⅲ评估192周龄时婴儿的躯体生长或畸形、骨密度(BMD)和神经发育情况。 

 

在180名符合条件婴儿中，176名婴儿入组，145名婴儿完成了长期随访(对照组：75名；替诺福韦治疗组：70名)。替诺福韦治疗组，胎儿接触替诺福韦的平均时间为8.57±0.53周。

在第192周时，两组的先天性畸形率相似。对照组和替诺福韦治疗组分别与国家标准比较，男孩的平均体重显著较高，而且在正常范围内。其他预定的结果(头围、身高、骨密度、认知、运动、社交情绪和适应行为测量)在组差异均有统计学意义。

   

胎儿暴露于替诺福韦的婴儿在第192周时身体生长、骨密度和神经发育正常。本研究为胎儿暴露于母体替诺福韦预防乙型肝炎传播的长期安全性提供了证据。

摘译自：PAN CQ, DAI E, DUAN Z, et al. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China[J]. Gut, 2021.

吉林大学第一医院感染病中心肝病科

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1710277, encodeId=103d1e10277fa, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 20 14:50:17 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753588, encodeId=5d3b1e5358840, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 02 16:50:17 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005109, encodeId=3a442005109f4, content=<a href='/topic/show?id=e052635332c' target=_blank style='color:#2F92EE;'>#母婴阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63533, encryptionId=e052635332c, topicName=母婴阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Sep 12 14:50:17 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990286, encodeId=f323199028629, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Jul 12 19:50:17 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428651, encodeId=cc4c1428651f4, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439403, encodeId=465814394031c, content=<a href='/topic/show?id=45616352128' target=_blank style='color:#2F92EE;'>#母婴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63521, encryptionId=45616352128, topicName=母婴)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2022-01-20 41514497@qq.com

    #阻断#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1710277, encodeId=103d1e10277fa, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 20 14:50:17 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753588, encodeId=5d3b1e5358840, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 02 16:50:17 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005109, encodeId=3a442005109f4, content=<a href='/topic/show?id=e052635332c' target=_blank style='color:#2F92EE;'>#母婴阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63533, encryptionId=e052635332c, topicName=母婴阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Sep 12 14:50:17 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990286, encodeId=f323199028629, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Jul 12 19:50:17 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428651, encodeId=cc4c1428651f4, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439403, encodeId=465814394031c, content=<a href='/topic/show?id=45616352128' target=_blank style='color:#2F92EE;'>#母婴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63521, encryptionId=45616352128, topicName=母婴)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-09-02 hanhaisha2020

    #研究发现#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1710277, encodeId=103d1e10277fa, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 20 14:50:17 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753588, encodeId=5d3b1e5358840, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 02 16:50:17 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005109, encodeId=3a442005109f4, content=<a href='/topic/show?id=e052635332c' target=_blank style='color:#2F92EE;'>#母婴阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63533, encryptionId=e052635332c, topicName=母婴阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Sep 12 14:50:17 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990286, encodeId=f323199028629, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Jul 12 19:50:17 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428651, encodeId=cc4c1428651f4, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439403, encodeId=465814394031c, content=<a href='/topic/show?id=45616352128' target=_blank style='color:#2F92EE;'>#母婴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63521, encryptionId=45616352128, topicName=母婴)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-09-12 lfyang

    #母婴阻断#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1710277, encodeId=103d1e10277fa, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 20 14:50:17 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753588, encodeId=5d3b1e5358840, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 02 16:50:17 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005109, encodeId=3a442005109f4, content=<a href='/topic/show?id=e052635332c' target=_blank style='color:#2F92EE;'>#母婴阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63533, encryptionId=e052635332c, topicName=母婴阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Sep 12 14:50:17 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990286, encodeId=f323199028629, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Jul 12 19:50:17 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428651, encodeId=cc4c1428651f4, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439403, encodeId=465814394031c, content=<a href='/topic/show?id=45616352128' target=_blank style='color:#2F92EE;'>#母婴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63521, encryptionId=45616352128, topicName=母婴)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-07-12 fengxx

    #长期安全性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1710277, encodeId=103d1e10277fa, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 20 14:50:17 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753588, encodeId=5d3b1e5358840, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 02 16:50:17 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005109, encodeId=3a442005109f4, content=<a href='/topic/show?id=e052635332c' target=_blank style='color:#2F92EE;'>#母婴阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63533, encryptionId=e052635332c, topicName=母婴阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Sep 12 14:50:17 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990286, encodeId=f323199028629, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Jul 12 19:50:17 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428651, encodeId=cc4c1428651f4, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439403, encodeId=465814394031c, content=<a href='/topic/show?id=45616352128' target=_blank style='color:#2F92EE;'>#母婴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63521, encryptionId=45616352128, topicName=母婴)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-05-15 yhj-time

    #替诺福韦#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1710277, encodeId=103d1e10277fa, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu Jan 20 14:50:17 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753588, encodeId=5d3b1e5358840, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Sep 02 16:50:17 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005109, encodeId=3a442005109f4, content=<a href='/topic/show?id=e052635332c' target=_blank style='color:#2F92EE;'>#母婴阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63533, encryptionId=e052635332c, topicName=母婴阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Sep 12 14:50:17 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990286, encodeId=f323199028629, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Mon Jul 12 19:50:17 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428651, encodeId=cc4c1428651f4, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439403, encodeId=465814394031c, content=<a href='/topic/show?id=45616352128' target=_blank style='color:#2F92EE;'>#母婴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63521, encryptionId=45616352128, topicName=母婴)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 15 09:50:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-05-15 zhouqu_8

    #母婴#

    0

相关资讯

Aliment Pharmacol Ther：CHB携带者：替诺福韦酯能显著降低血清脂蛋白水平

替诺福韦酯（TDF）和恩替卡韦（ETV）是慢性乙型肝炎（CHB）的一线治疗方法。研究显示，TDF对人类免疫缺陷病毒阳性（HIV+）个体具有降脂作用，但是其对CHB患者脂类和心血管疾病（CVD）风险的影响尚不清楚。2017年9月，发表在《Aliment Pharmacol Ther.》的一项回顾性队列研究表明，替诺福韦酯能显著降低CHB携带者血清脂蛋白水平。

慢性乙肝一线治疗药物替诺福韦酯等大降价

对专利药品、独家生产药品，建立公开透明、多方参与的药品价格谈判机制，是深化医药卫生体制改革、推进公立医院药品集中采购、降低广大患者用药负担的重要举措。2016年5月20日，首批国家药品价格谈判结果向社会公布，其中有慢性乙肝一线治疗药物替诺福韦酯，非小细胞肺癌靶向治疗药物埃克替尼和吉非替尼。与之前公立医院的采购价格比较，3种谈判药品价格降幅均在50%以上，与周边国家（地区）趋同。 2015年10月

Hepatology：替诺福韦酯或可成为青少年HBV患者的有效疗法

一项临床试验近日研究发现，成年人的抗病毒药物替诺福韦酯（tenofovir DF），对于治疗携带乙型肝炎病毒（HBV）的青少年携带者是安全且有效的，相关研究成果刊登于国际杂志Hepatology上。 慢性乙肝在全球影响着大约3亿5千万人的健康及生活，每年有600，000人死于慢性乙肝。研究者Karen表示，感染HBV的儿童更易发展为严重的肝脏疾病，而且很有可能因为严重的肝脏疾病死亡。替诺福韦酯是

J Hepatol：无肝纤维化HBeAg阴性患者能停用替诺福韦酯吗？

替诺福韦酯（TDF）是一种新型核苷酸类逆转录酶抑制剂，近来有研究显示其有很强的抑制乙肝病毒（HBV）作用。2017年11月，发表在《J Hepatol》上的一项研究，考察了无肝纤维化HBeAg阴性患者中停用TDF治疗的可能性。

BMC Gastroenterol：替诺福韦酯预防HBV母婴传播安全有效

在HBV感染高流行区，母婴传播是导致HBV感染的重要传播途径，强效、高耐药屏障的替诺福韦酯（TDF）为妊娠B级抗HBV药物。

Hepatology：替诺福韦酯能降低乙肝孕妈妈后代乙肝传染(PreMIT研究）

乙肝孕妇在中国并不少见，很多孕妇及家属都会担心其宫内胎儿的情况。目前替诺福韦酯(TDF)在临床上对于普通人群应用较广，并且效果得到肯定。其具有抑制乙型肝炎病毒(HBV)复制的作用，同时可以在一定程度能降低体内相关转氨酶水平，起到保护肝脏的作用。但是目前关于替诺福韦酯(TDF)在孕妇中的运用、对于减少乙型肝炎病毒(HBV)垂直传播的有效性和安全性并不明确。